TrialPath
Recruiting

The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel Disease

NCT06913998 · National Taiwan University Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
In inflammatory bowel disease (IBD), thiopurines play an important role in maintenance of steroid-free remission but possess risk of life-threatening neutropenia, which is associated with gene variants of NUDT15 in Asians. In order to better incorporate thiopurines in clinical practice, the investigators aim to summarize the prevalence and impacts of NUDT15 variation in IBD in Taiwan. The study will include participants who were diagnosed with inflammatory disease and followed up at National Taiwan University Children's Hospital. The investigators will check the NUDT15 gene test, if the participant agrees to do an additional blood test. The result of the gene test will be analyzed and compared with other clinical data.
Eligibility criteria
Inclusion Criteria: * Participants who are diagnosed with inflammatory bowel disease. Exclusion Criteria: * Participants who refused to have blood test for NUDT15 gene evaluation.
Study design
Enrollment target: 65 participants
Age groups: child, adult
Timeline
Starts: 2023-12-27
Estimated completion: 2026-11
Last updated: 2025-04-08
Primary outcomes
  • Neutropenia (2 years)
Sponsor
National Taiwan University Hospital · other
Contacts & investigators
ContactWei-Ting Chen, MD · contact · DBE98@tepch.gov.tw · +886-2-2312-3456
ContactJia-Feng Wu, MD, PhD · contact · wjf@ntu.edu.tw · +886-2-2312-3456
All locations (1)
National Taiwan University HospitalRecruiting
Taipei, Taiwan
The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel Disease · TrialPath